HomeAI · summaries
Storia in 3 fonti
FDA hearing on Amgen's Tavneos will include findings from an independent review
An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing later this month with the FDA which could determine whether the rare disease treatment remain | An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing later this month with the FDA which could determine whether the rare disease treatment remains on the market.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
As Gilead's Trodelvy stumbles in first-line lung cancer, all eyes turn to Merck, AZ and Daiichi rivals
Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to patients with first-line non-small cell lung cancer…
- ·
FDA hearing on Amgen's Tavneos will include findings from an independent review
An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing later this month with the FDA which could determine whether the rare…
